Meta-analysis: Its role in the drug approval process and the implications for Evidence Based Dentistry

References 

1. In: Webster's New Collegiate Dictionary. G & C, Merrian Company; 1975;p. 396
2. In:  Cooper H,  Hedges LV editor. The Handbook of Research Synthesis. Russell Sage Foundation; 1994;p. 537–538
3. New Drugs, 21 U.S.C. Sect. 355 (d)(2003).
4. Drug Amendments of 1962 (Harris-Kefauver Act), Pub. L. No. 87–781, 76 Stat. 780(October 10, 1962).
5. Temple R. History of FDA: policy developments in regulatory approval. Stat Med. 2002;21(19):2939–2948
   • MEDLINE
   • CrossRef
6. Adequate and Well-Controlled Studies, 21 C.F.R. Sect. 314.126(2003).
7. Hyman FN, Welch ME, Cheever JR. Regulatory issues for evaluation of therapies to prevent or arrest disease progression. Ann Periodontol. 1997;2(1):166–179
   • MEDLINE
   • CrossRef
8. Refusal to Approve and Application, 21 C.F.R. Sect. 314.125(b)(4)(2003).
9. Food and Drug Administration [homepage on the Internet]. Maryland: Food and Drug Administration; c1995–2003 [updated December 9, 2003; cited December 11, 2003]. CDER Freedom of Information New Drug Approval Packages; [one screen]. Available from: http://www.fda.gov/cder/foi/nda.index.htm.
10. Food and Drug Administration (FDA) Modernization Act of 1997, Pub. L. No. 105–115, 111 Stat. 2296 (Nov 21, 1997).
11. Gilbertson WE. FDA's Review of OTC Drugs. In:  Covington T,  Lawson L,  Young L editor. Handbook of Nonprescription Drugs. Washington, D.C: American Pharmaceutical Association; 1993;p. 21–37
12. D'Agostino RB, Weintraub M, et al.  The effectiveness of antihistamines in reducing severity of runny nose and sneezing: a meta-analysis. Clin Pharmacol Ther. 1998;64(6):579–596
    • MEDLINE
    • CrossRef
13. Hopkins RJ, Giradri LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996;110(4):1244–1252
    • Abstract
    • Full-Text PDF (217 KB)
    • CrossRef
14. Kazempour K, Kammerman LA, Farr SS. Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(Suppl 2):S97–106
15. Li Qian. FDA's Arthritis Advisory Committee, February 2001.